Medicamen Biotech Limited (MEDICAMEQ) AI Stock Analysis

• Market Cap: ₹5.29B
• Dividend Yield: 0.26%
• Average Volume (3M): 2.40K
• Price to Earnings (P/E): 47.6
• Beta (1Y): 1.62
• Revenue Growth: -9.16%
• EPS Growth: 49.09%
• Country: IN
• Employees: 378
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 1.97
• Shares Outstanding: 13,562,815
• 10 Day Avg. Volume: 3,620
• 30 Day Avg. Volume: 2,395
• PEG Ratio: -2.50
• Price to Book (P/B): 2.95
• Price to Sales (P/S): 3.86
• P/FCF Ratio: -52.55
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 57 Neutral
• Price Target: ₹409.00 ▲(11.47% Upside)

The score is primarily held back by weak cash flow (negative operating and free cash flow) and a high valuation (P/E 44.186 with a low dividend yield). These are partially offset by a stable balance sheet and relatively healthy operating margins, while technical signals remain mixed with negative MACD.

Positive Factors

Balance Sheet Strength

Moderate leverage and a solid equity ratio provide structural solvency and financial flexibility. This foundation reduces insolvency risk, supports access to capital when needed, and enables the firm to sustain operations, finance strategic initiatives, and absorb industry shocks over the medium term.

Operational Margins

Relatively healthy EBIT/EBITDA margins point to efficient core operations and cost control. Sustained margins support internal cash generation potential, underpin profitability even if revenues fluctuate, and provide room to invest in R&D or commercial expansion over the coming months.

Diversified Revenue Streams

A broad product mix (generics, APIs, biopharma) and multiple channels (direct sales, CMOs, partnerships, licensing) reduce concentration risk. Diversification helps stabilize revenues across cycles, enables cross-selling, and supports longer-term growth opportunities across therapeutic areas.

Negative Factors

Weak Cash Generation

Persistent negative operating and free cash flow undermines liquidity and financial flexibility. Over months this constrains funding for capex, R&D, or paying down debt, may force external financing at adverse terms, and raises risk for execution of strategic initiatives if not remediated.

Declining Revenue Trend

A near-term revenue decline indicates loss of top-line momentum and potential market share pressures. Continued contraction limits scale benefits, pressures margins and cash conversion, and restricts resources available for product development and market expansion over a 2–6 month horizon.

Profitability Volatility

Volatile net margins and inconsistent revenue undermine earnings predictability and planning. This increases forecasting risk, complicates capital allocation, and can reduce investor and partner confidence, making sustained investment in long-term projects or strategic moves more difficult.

Medicamen Biotech Limited Business Overview & Revenue Model

Company Description

Medicamen Biotech Limited manufactures and sells pharmaceutical formulations in India. The company offers its products in various forms, including tablets, capsules, liquid and dry syrups, and ointments. It also provides oral rehydration solution, mouth wash, and dental care products. The company was incorporated in 1993 and is based in New Delhi, India.

How the Company Makes Money

Medicamen Biotech Limited generates revenue primarily through the sale of its pharmaceutical products, including generics and APIs, to healthcare providers, hospitals, and pharmacies. The company benefits from its extensive product portfolio, which allows it to capture diverse market segments. Key revenue streams include direct sales, contract manufacturing, and strategic partnerships with other pharmaceutical firms for co-development and distribution of products. Additionally, MEDICAMEQ may engage in licensing agreements for its proprietary technologies or formulations, further diversifying its income sources. The company's commitment to research and development enhances its competitive advantage, potentially leading to new product launches that can significantly boost revenue.

Medicamen Biotech Limited Financial Statement Overview

Summary

Medicamen Biotech Limited shows a mixed financial profile. Strong EBIT and EBITDA margins indicate efficient cost management, but inconsistent revenue growth and negative free cash flow pose liquidity risks. The balance sheet is stable with moderate leverage and strong equity ratios, enhancing financial stability.

Income Statement

Medicamen Biotech Limited has shown a mixed performance in its income statement. The gross profit margin has been moderately strong, but net profit margin has seen some volatility. Revenue growth has been inconsistent, with significant fluctuations year over year. Notably, EBIT and EBITDA margins are relatively healthy, indicating efficient cost management despite variability in revenue.

Balance Sheet

The balance sheet of Medicamen Biotech Limited reflects a stable financial structure. The company maintains a reasonable debt-to-equity ratio, suggesting moderate leverage. The return on equity is satisfactory, reflecting effective use of equity capital. The equity ratio is solid, showing a strong equity position relative to total assets, which is favorable for long-term solvency.

Cash Flow

Medicamen Biotech Limited's cash flow statement reveals challenges, primarily with negative free cash flow over the past years, indicating potential liquidity issues. The operating cash flow to net income ratio is concerning, as operating cash flow has been negative, suggesting difficulties in converting net income into cash. This could pose risks to financial flexibility if it persists.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	1.63B	1.63B	1.79B	1.41B	1.15B	1.13B
Gross Profit	704.27M	389.90M	852.01M	687.74M	479.88M	335.16M
EBITDA	211.56M	201.02M	245.66M	277.12M	258.07M	204.25M
Net Income	89.48M	71.08M	109.31M	148.44M	148.98M	121.29M
Balance Sheet
Total Assets	0.00	2.97B	2.95B	2.79B	2.26B	1.94B
Cash, Cash Equivalents and Short-Term Investments	37.59M	37.59M	147.86M	207.79M	38.25M	38.91M
Total Debt	0.00	332.53M	311.12M	257.09M	257.96M	188.19M
Total Liabilities	-2.13B	841.04M	875.67M	851.03M	792.24M	611.18M
Stockholders Equity	2.13B	2.13B	2.07B	1.93B	1.46B	1.33B
Cash Flow
Free Cash Flow	0.00	-119.32M	-130.31M	-128.94M	-44.99M	-51.94M
Operating Cash Flow	0.00	-98.59M	-67.44M	-62.93M	41.09M	127.72M
Investing Cash Flow	0.00	-23.78M	-55.63M	-58.80M	-84.73M	-178.13M
Financing Cash Flow	0.00	12.16M	63.13M	291.27M	42.98M	58.39M

Medicamen Biotech Limited Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 366.90
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:MEDICAMEQ, the sentiment is Positive. The current price of 366.9 is below the 20-day moving average (MA) of 383.31, below the 50-day MA of 390.91, and below the 200-day MA of 392.86, indicating a neutral trend. The MACD of -0.73 indicates Negative momentum. The RSI at 53.12 is Neutral, neither overbought nor oversold. The STOCH value of 41.17 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:MEDICAMEQ.

Medicamen Biotech Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VENUSREM	72 Outperform	₹9.72B	13.81	―	―	13.32%	218.38%
INDSWFTLAB	70 Outperform	₹7.40B	2.57	―	―	-37.70%	-19.79%
SAKAR	66 Neutral	₹8.34B	43.00	―	―	24.20%	55.01%
ZIMLAB	63 Neutral	₹3.33B	50.60	―	―	-5.82%	-59.22%
MEDICAMEQ	57 Neutral	₹5.29B	47.58	―	0.26%	-9.16%	49.09%
NECLIFE	52 Neutral	₹4.09B	-1.13	―	―	-30.27%	-3470.06%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%